Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Niagen Bioscience (NAGE) over the last 13 years, with Q3 2025 value amounting to $2.7 million.

  • Niagen Bioscience's Non-Current Deffered Revenue rose 368.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 368.36%. This contributed to the annual value of $2.6 million for FY2024, which is 2210.81% down from last year.
  • Latest data reveals that Niagen Bioscience reported Non-Current Deffered Revenue of $2.7 million as of Q3 2025, which was up 368.36% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Non-Current Deffered Revenue registered a high of $4.4 million during Q2 2021, and its lowest value of $2.6 million during Q3 2024.
  • Over the past 5 years, Niagen Bioscience's median Non-Current Deffered Revenue value was $3.8 million (recorded in 2023), while the average stood at $3.6 million.
  • In the last 5 years, Niagen Bioscience's Non-Current Deffered Revenue surged by 1625.65% in 2021 and then tumbled by 3223.86% in 2024.
  • Quarter analysis of 5 years shows Niagen Bioscience's Non-Current Deffered Revenue stood at $4.3 million in 2021, then dropped by 7.96% to $4.0 million in 2022, then fell by 17.22% to $3.3 million in 2023, then decreased by 22.11% to $2.6 million in 2024, then grew by 3.68% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.6 million during Q1 2025.